^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NTRK-ROS1 fusion

    i
    Other names: ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1, NTRK | Neurotroph
    Entrez ID:
    6098
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts) (ESMO 2023)
    Conclusions ctDNA testing detects primary resistance to EGFR inhibition in a subgroup of untreated, RAS/BRAF WT mCRC pts, thus serving as a prognostic classifier and providing additional value above routine tumour profiling. Updated results will be presented.
    Clinical • Circulating tumor DNA • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SMAD4 (SMAD family member 4) • RAS (Rat Sarcoma Virus) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • HER-2 amplification • MET amplification • EGFR amplification • PTEN mutation • BRAF wild-type • ALK fusion • RAS mutation • ROS1 fusion • NTRK-ROS1 fusion
    |
    Guardant360® CDx